Using a swallowed sensor to support prep adherence in young men
Part of Immune system & allergy, Infections clinical trials.
This study tests a tiny sensor you swallow that lets your phone know when you take your PrEP pill. It aims to help young men stick to their HIV prevention routine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 to 24.
- You are interested in taking PrEP (a daily pill to prevent HIV) for at least 6 months.
- You meet at least one sexual risk criterion (like having an HIV-positive partner, recent STI, or inconsistent condom use).
- You are HIV negative.
- You do not have severe kidney problems, allergies to adhesives, or major gastrointestinal issues.
- You are not taking certain medications (like diuretics or some osteoporosis drugs) outside of the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an all-in-one HIV prevention package for young men at higher risk of HIV. It combines a new long-acting PrEP (injectable HIV prevention) with mobile health support and sexually transmitted infection prevention. The goal is to see if this comprehensive approach works better than standard care.
This study tests a new approach to help young gay and bisexual men who take PrEP medication prevent HIV but sometimes miss doses or have condomless sex. It aims to see if behavioral strategies can improve adherence to PrEP and reduce risky behaviors.
This study helps young people who are at risk for HIV get on PrEP—a daily pill or shot that prevents HIV. It tests different ways to help you start and stay on PrEP, with care available at clinics or in your community.
This study tests a special pill that has a sensor inside, which sends information to your doctor or care team to help you remember to take your HIV medication. It is for people who sometimes miss doses and want extra support.
This study tests a '2-1-1' on-demand PrEP strategy for cisgender men who have sex with men. It aims to see if taking PrEP only around the time of sex is safe and effective. If you are interested in starting or currently taking PrEP this way, you may be eligible.
This trial tests a new way to take HIV prevention medicine (PrEP) only around the time you have sex, using a pill called TAF/FTC. It aims to see if this 'on-demand' method is effective, safe, and acceptable, and could offer a more flexible option than taking a pill every day.
Hear when a new Human Immunodeficiency Virus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.